S
11.24
0.16 (1.44%)
| Previous Close | 11.08 |
| Open | 11.24 |
| Volume | 1,400 |
| Avg. Volume (3M) | 1,211,251 |
| Market Cap | 24,444,864,512 |
| Price / Earnings (Forward) | 588.24 |
| Price / Sales | 6.26 |
| Price / Book | 1.56 |
| 52 Weeks Range | |
| Earnings Date | 29 Oct 2024 |
| Profit Margin | -100.90% |
| Operating Margin (TTM) | -56.81% |
| Diluted EPS (TTM) | -2.12 |
| Quarterly Revenue Growth (YOY) | 53.20% |
| Total Debt/Equity (MRQ) | 44.20% |
| Current Ratio (MRQ) | 2.00 |
| Operating Cash Flow (TTM) | -1.45 B |
| Levered Free Cash Flow (TTM) | -1.58 B |
| Return on Assets (TTM) | -10.52% |
| Return on Equity (TTM) | -26.94% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (HK) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | JUNSHI BIO | - | - |
AIStockmoo Score
-0.4
| Analyst Consensus | 0.0 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | -2.0 |
| Average | -0.38 |
Similar Stocks
| Stock | Market Cap | DY | P/E (TTM) | P/B |
|---|---|---|---|---|
| JUNSHI BIO | 24 B | - | - | 1.56 |
| ASYMCHEM | 29 B | 3.60% | 21.01 | 1.02 |
| ZAI LAB | 23 B | - | - | 4.38 |
| REMEGEN | 14 B | - | - | 2.74 |
| AKESO | 55 B | - | - | 9.50 |
| INNOVENT BIO | 53 B | - | - | 4.54 |
|
Shanghai Junshi Biosciences Co Ltd is a China-based biotechnology companyy with all-round capabilities in innovative drug discovery and development, clinical research on a global scale, large-scale production capacity to commercialization on the full industry chain. Aiming to develop first-in-class or bestin-class drugs by way of original innovation and co-development. Companies operations are located in the PRC and the USA. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Mid Core |
| % Held by Insiders | 22.43% |
| % Held by Institutions | 22.07% |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |